Digging into the supporting research raises questions
by Adam Taggart
Chris Martenson’s Peak Prosperity
The world is cheering the news that Gilead Science’s antiviral drug remdesivir is showing a “clear cut positive effect in diminishing time to recover” for those infected with the covid-19 virus.
President Trump says he is now pushing the FDA to fast-track remdesivir through the approvals process.
So the media is filled with joyous headlines and the stock market had a banner up day.
But as with most announcements lately, digging into the supporting research raises lots of questions about the news.
First off, China’s published studies of remdesivir show little to no evidence that the drug makes any difference either in clinical improvement or mortality improvement.